Metabolic correlates of toluene abuse: decline and recovery of function in adolescent animals.
BACKGROUND
Children and adolescents will readily abuse household products that contain solvents such as toluene. It is likely that reinforcing exposures to toluene alter brain glucose metabolism.


OBJECTIVE
Using an animal model of drug reinforcement, we sought to identify a metabolic signature of toluene abuse in the adolescent rodent brain. Small animal PET (microPET), in combination with the glucose analog radiotracer, (18)FDG, were used to evaluate the metabolic consequences of inhaled toluene.


METHODS
The exposure protocol paralleled our previously established method for assessing the conditioned reinforcing effects of toluene (5,000 ppm) using the conditioned place preference (CPP) paradigm. Animals were scanned at baseline and 2 h after the last exposure. Follow-up (18)FDG scans occurred 1 day, 3 weeks, and 2 months later.


RESULTS
After six pairings, 38% of the animals preferred the toluene paired chamber and 25% were averse. The immediate metabolic effect in toluene-exposed animals was a 20% decline in whole brain (18)FDG uptake. Twenty-four hours following the last exposure, the whole brain decline was 40%, and 2 months later, the decline was 30% of pretoluene levels. A region-by-region analysis demonstrated significant additional decreases in the pons, cerebellum, striatum, midbrain, temporal cortex, and hippocampus. Two months after toluene cessation, regions of complete metabolic recovery were the thalamus and cerebellum; however, the temporal cortex did not recover.


CONCLUSIONS
Brain uptake of (18)FDG appears to be a useful tool for examining the metabolic impact of toluene abuse, which include a profound decline followed by region-specific recovery after cessation.
Schiffer
Wynne K
WK
Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973, USA. wynne@bnl.gov
Lee
Dianne E
DE
Alexoff
David L
DL
Ferrieri
Rich
R
Brodie
Jonathan D
JD
Dewey
Stephen L
SL
D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D001931:Brain Mapping; D004195:Disease Models, Animal; D019788:Fluorodeoxyglucose F18; D019570:Inhalation Exposure / Q000009:adverse effects*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012054:Reinforcement, Psychology; D012997:Solvents / Q000633:toxicity*; D019966:Substance-Related Disorders / Q000000981:diagnostic imaging / Q000209:etiology / Q000378:metabolism* / Q000523:psychology; D014050:Toluene / Q000633:toxicity*; D014055:Tomography, Emission-Computed
D012997:Solvents; D019788:Fluorodeoxyglucose F18; D014050:Toluene